GlobeNewswire·Nov 12, 2026, 4:01 PM ET

Electra Therapeutics Reports Third Quarter 2026 Financial Results and Recent Portfolio Highlights

Electra Therapeutics completed a $350 million IPO in September 2026 to fund its SIRP-targeting portfolio.
Ipsoprubart is advancing in a global registrational program for secondary hemophagocytic lymphohistiocytosis (sHLH) with enrollment completion expected in the second half of 2027.
Ipsoprubart is being evaluated in a Phase 1 trial for T/NK cell malignancies, with initial data expected in the second half of 2027.
ELA822 healthy volunteer data is expected in the first half of 2027, followed by a first-in-disease trial initiation planned for mid-2027.
Ipsoprubart demonstrated 100% overall survival at eight weeks & a 100% overall response rate at four weeks in a Phase 1b trial for malignancy-associated HLH.
Eight sHLH patients with underlying lymphomas showed objective tumor responses, including seven complete responses, in Phase 1b & Expanded Access Program data.
Electra reported cash, cash equivalents, & marketable securities totaling $402.5 million as of September 30, 2026, with funds expected to support operations into 2029.
Third quarter 2026 R&D expenses were $17.3 million, G&A expenses were $7.8 million, resulting in a net loss of $23.9 million.
Two abstracts regarding sHLH burden & SIRP expression were accepted for presentation at the 2026 American Society of Hematology Annual Meeting on December 13, 2026.
The registrational program includes the SURPASS Phase 2/3 trial & the COMPASS retrospective natural history study to serve as an external control.